Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...
Data sources Cochrane Central, PsycINFO, Embase, Medline and CINAHL. Eligibility criteria Peer-reviewed, randomised controlled trials, in English (1990–present), which examined the effects of exercise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback